| |
Volume of tumor, mm3 (mean ± SD)
|
| Group* |
Day 0 |
Day 21 |
|
| CL-1 implantation |
... |
... |
| Ad-CMV-CD + 5-FC |
637 ± 91 |
1952 ± 427 |
| Ad-PSMAE-P–CD + 5-FC |
516 ± 105 |
2568 ± 487 |
| Ad-PSMAE-P–CD + saline |
533 ± 94 |
4975 ± 713 |
| Ad-CMV-CD + saline |
616 ± 110 |
5072 ± 658 |
| 5-FC only |
572 ± 102 |
4784 ± 634 |
| Saline only |
584 ± 96 |
5458 ± 726 |
| A549 implantation |
... |
... |
| Ad-CMV-CD + 5-FC |
567 ± 113 |
2045 ± 443 |
| Ad-PSMAE-P–CD + 5-FC |
533 ± 98 |
6455 ± 735 |
|
| *In CL-1 implanted groups, after treatment, there was no difference between
Ad-CMV-CD+5-FC and Ad-PSMAE-P–CD+5-FC groups (P =
.305); however, there were significant differences among Ad-CMV-CD+5-FC,
Ad-PSMAE-P–CD+5-FC, and control groups (P <
.0001). In A549 implanted groups, there was significant difference between
Ad-CMV-CD+5-FC and Ad-PSMAE-P–CD+5-FC groups (P =
.0003) |
|
